mCRPC
Metastatic castration-resistant prostate cancer
Advertisement
Results of the BOP trial have shown 64Cu SAR-Bombesin can detect lesions in BCR prostate cancer that is PSMA PET-negative.
SNMMI convened an autonomous workgroup to review prospective phase 2/3 clinical trials that used 177Lu-PSMA-617.
A PSA decrease ≥30% after the first 2 cycles of 177Lu PSMA can serve as an early marker of response in clinical practice.
As mCRPC cells are deficient in retinoblastoma proteins, they have a hypersensitivity to taxanes such as cabazitaxel.
The trial’s 2 primary end points were PFS and overall survival, with a secondary end point of objective response rate.
Drs. Marshall, Reimers, and Dorff discuss toxicities from single-agent and combination-based HR inhibitors.
Drs. Marshall, Reimers, and Dorff discuss PARP inhibitor strategies for BRCA-mutated patients throughout the care continuum.
Foundation Medicine’s comprehensive genomic profiling test identifies mCRPC harboring BRCA1/2-positive mutations.
The FDA granted approval to AKEEGA given with prednisone for patients with BRCA-positive mCRPC.
A meta-analysis sought to determine the efficacy of systemic therapies in patients with PCa and poor performance status.
The VISION trial assigned patients to receive either [177Lu]Lu-PSMA-617 plus standard of care or standard of care alone.
New research identified genomic features and post-therapeutic SPECT/CT parameters as predictors of response to Pluvicto.
The US FDA granted approval to talazoparib in combination with enzalutamide for adult patients with HRR-mutated mCRPC.
Updated AUA/SUO Guideline on Advanced Prostate Cancer Offers New Recommendations on Imaging, Testing
The updated guideline emphasizes the use of PSMA PET for periodic staging, as well as the use of ADT.
Drs. Fizazi and Wallis detail the latest updates regarding TALAPRO-2 for patients with mCRPC and HRR gene alterations.
Drs. Armstrong and Wallis discuss the design of an AI-derived pathology-based biomarker for localized high-risk prostate.
The combination treatment of dual-PSMA targeting with mAb and SML is feasible, and a follow-up study is in progress.
The FDA has approved the combination treatment of olaparib with abiraterone and prednisone for BRCA-mutated mCRPC.
Results outlined patient-reported outcomes from the TALAPRO-2 trial on first-line talazoparib plus enzalutamide for mCRPC.
Dr. Dorff explains how the prognostic model from the CALGB 90401 trial provides accurate information to patients with mCRPC.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.